Compare Johnson & Johnson (JNJ) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs S&P500 ETF — how do they compare? Johnson & Johnson trades at $249.85 (market cap $598.96B), while S&P500 ETF trades at $746.78. The key difference: Johnson & Johnson pays a 2.15% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals.
| JNJ | SPY | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $759.55 |
52-Week Low | $164.36 | $621.75 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
SPY trades at $742.21, down 0.13% with a bearish technical outlook. The S&P 500 index faces pressure, declining 1.6% last week and trading below its 50-day moving average. Recent news highlights concerns about market concentration in tech stocks and elevated valuations, though some analysts see potential for continued gains. A dividend of $1.90 is scheduled for July 2026.
The ETF's outlook is mixed amid technical weakness and valuation debates. While earnings season shows strength, market concentration and fee comparisons with sister funds present risks. The bearish technical signal suggests near-term caution, though long-term index exposure remains a core portfolio strategy for many investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
